Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry

Helen E. Jo,Tamera J. Corte,Ian Glaspole,Christopher Grainge,Peter M. A. Hopkins,Yuben Moodley,Paul N. Reynolds,Sally Chapman,E. Haydn Walters,Christopher Zappala,Heather Allan,Gregory J. Keir,Wendy A. Cooper,Annabelle M. Mahar,Samantha Ellis,Sacha Macansh,Nicole S. Goh
DOI: https://doi.org/10.1186/s12890-019-0846-2
IF: 3.1
2019-05-03
BMC Pulmonary Medicine
Abstract:<h3>Background and objective</h3><p>Gastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not improve IPF patient outcomes and may increase the risk of pulmonary infection.</p>
respiratory system
What problem does this paper attempt to address?